Literature DB >> 25816790

Drugs of abuse and Parkinson's disease.

Leah R Mursaleen1, Jonathan A Stamford2.   

Abstract

The term "drug of abuse" is highly contextual. What constitutes a drug of abuse for one population of patients does not for another. It is therefore important to examine the needs of the patient population to properly assess the status of drugs of abuse. The focus of this article is on the bidirectional relationship between patients and drug abuse. In this paper we will introduce the dopaminergic systems of the brain in Parkinson's and the influence of antiparkinsonian drugs upon them before discussing this synergy of condition and medication as fertile ground for drug abuse. We will then examine the relationship between drugs of abuse and Parkinson's, both beneficial and deleterious. In summary we will draw the different strands together and speculate on the future merit of current drugs of abuse as treatments for Parkinson's disease.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cannabis; Cocaine; MDMA; MPTP; Methamphetamine; Nucleus accumbens

Mesh:

Substances:

Year:  2015        PMID: 25816790     DOI: 10.1016/j.pnpbp.2015.03.013

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  7 in total

1.  Prolonged increase in ser31 tyrosine hydroxylase phosphorylation in substantia nigra following cessation of chronic methamphetamine.

Authors:  Michael F Salvatore; Vicki A Nejtek; Habibeh Khoshbouei
Journal:  Neurotoxicology       Date:  2018-05-18       Impact factor: 4.294

2.  Endoplasmic Reticulum Stress Mediates Methamphetamine-Induced Blood-Brain Barrier Damage.

Authors:  Xiaojuan Qie; Di Wen; Hongyan Guo; Guanjie Xu; Shuai Liu; Qianchao Shen; Yi Liu; Wenfang Zhang; Bin Cong; Chunling Ma
Journal:  Front Pharmacol       Date:  2017-09-14       Impact factor: 5.810

3.  Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study).

Authors:  Marina Peball; Mario Werkmann; Philipp Ellmerer; Raphaela Stolz; Dora Valent; Hans-Günther Knaus; Hanno Ulmer; Atbin Djamshidian; Werner Poewe; Klaus Seppi
Journal:  J Neural Transm (Vienna)       Date:  2019-05-25       Impact factor: 3.575

4.  Perceived Health, Psychological Distress, and Subjective Well-Being among Older Adults with Parkinson's Disease: A Cross-Lagged Analysis.

Authors:  Sunwoo Lee
Journal:  Int J Environ Res Public Health       Date:  2021-11-29       Impact factor: 3.390

5.  Hypoxia and Alpha-Synuclein: Inextricable Link Underlying the Pathologic Progression of Parkinson's Disease.

Authors:  Mengyuan Guo; Xunming Ji; Jia Liu
Journal:  Front Aging Neurosci       Date:  2022-07-26       Impact factor: 5.702

Review 6.  Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease.

Authors:  Carla Ferreira; Catarina Almeida; Sandra Tenreiro; Alexandre Quintas
Journal:  Life (Basel)       Date:  2020-06-11

7.  Substance Use Disorders in Patients With Parkinson's Disease and Adverse Hospitalization Outcomes: A National Inpatient Study.

Authors:  Jaskaranpreet Kaur; Ramneek K Sandhu; Khadija T Kubra; Johanna S Canenguez Benitez; Henry K Onyeaka; Sabiha Akter; Ozge C Amuk Williams
Journal:  Cureus       Date:  2021-06-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.